Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice

Wei Hsiang Lin, Shiou Hwei Yeh, Wan Jen Yang, Kun Huei Yeh, Toshiyoshi Fujiwara, Aisuke Nii, Stanley Shi Chung Chang, Pei Jer Chen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells with high telomerase activity but not in normal cells lacking such activity. Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC. The oncolytic effect of Telomelysin has been investigated both in vitro using cell culture and in vivo using an immunocompetent in situ orthotopic HCC model. In this model, HCC developed spontaneously in the liver of HBx transgenic mice, which is pathologically and genetically similar to human HCC. In cell culture assay, Telomelysin lyses HCC cell lines at a low multiplicity of infection (MOI), ranging 0.77-6.35 (MOI [PFU/cell]). In the orthotopic HCC model, Telomelysin showed a potent oncolytic effect on HCC but spared normal liver tissue. Dose escalation analysis identified a safety dose of 1.25 × 108 PFU for this model. The effect of multiple injections of Telomelysin was also evaluated in this immunocompetent HCC model. We found that the virus replicates in HCC after a second intratumoral injection despite an immune response induced by the previous injection. This preclinical study shows that Telomelysin can be used for treatment of human HCC at an appropriate dosage and that its tumor-killing activity persists after multiple injections. What's new? More than 95 percent of hepatocellular carcinomas (HCCs) are associated with telomerase reverse transcriptase (hTERT) activation, which promotes cell immortality. In this study, the adenovirus Telomelysin demonstrated specific oncolytic activity in HCC cells with elevated hTERT. In addition, in mice with orthotopically growing HCC xenografts, the adenovirus slowed tumor growth, despite the generation of an immune response. The results suggest that Telomelysin may be useful in the treatment of HCC.

Original languageEnglish
Pages (from-to)1451-1462
Number of pages12
JournalInternational Journal of Cancer
Volume132
Issue number6
DOIs
Publication statusPublished - Mar 15 2013

Fingerprint

Telomerase
Transgenic Mice
Hepatocellular Carcinoma
Therapeutics
Adenoviridae
Injections
Neoplasms
Cell Culture Techniques
Viruses
Liver
Infection
Heterografts

Keywords

  • hepatocellular carcinoma
  • immunocompetent
  • oncolytic adenovirus
  • orthotopic
  • telomelysin

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. / Lin, Wei Hsiang; Yeh, Shiou Hwei; Yang, Wan Jen; Yeh, Kun Huei; Fujiwara, Toshiyoshi; Nii, Aisuke; Chang, Stanley Shi Chung; Chen, Pei Jer.

In: International Journal of Cancer, Vol. 132, No. 6, 15.03.2013, p. 1451-1462.

Research output: Contribution to journalArticle

Lin, Wei Hsiang ; Yeh, Shiou Hwei ; Yang, Wan Jen ; Yeh, Kun Huei ; Fujiwara, Toshiyoshi ; Nii, Aisuke ; Chang, Stanley Shi Chung ; Chen, Pei Jer. / Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. In: International Journal of Cancer. 2013 ; Vol. 132, No. 6. pp. 1451-1462.
@article{422fa9d517434acbbe509b66f1744fc1,
title = "Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice",
abstract = "The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells with high telomerase activity but not in normal cells lacking such activity. Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC. The oncolytic effect of Telomelysin has been investigated both in vitro using cell culture and in vivo using an immunocompetent in situ orthotopic HCC model. In this model, HCC developed spontaneously in the liver of HBx transgenic mice, which is pathologically and genetically similar to human HCC. In cell culture assay, Telomelysin lyses HCC cell lines at a low multiplicity of infection (MOI), ranging 0.77-6.35 (MOI [PFU/cell]). In the orthotopic HCC model, Telomelysin showed a potent oncolytic effect on HCC but spared normal liver tissue. Dose escalation analysis identified a safety dose of 1.25 × 108 PFU for this model. The effect of multiple injections of Telomelysin was also evaluated in this immunocompetent HCC model. We found that the virus replicates in HCC after a second intratumoral injection despite an immune response induced by the previous injection. This preclinical study shows that Telomelysin can be used for treatment of human HCC at an appropriate dosage and that its tumor-killing activity persists after multiple injections. What's new? More than 95 percent of hepatocellular carcinomas (HCCs) are associated with telomerase reverse transcriptase (hTERT) activation, which promotes cell immortality. In this study, the adenovirus Telomelysin demonstrated specific oncolytic activity in HCC cells with elevated hTERT. In addition, in mice with orthotopically growing HCC xenografts, the adenovirus slowed tumor growth, despite the generation of an immune response. The results suggest that Telomelysin may be useful in the treatment of HCC.",
keywords = "hepatocellular carcinoma, immunocompetent, oncolytic adenovirus, orthotopic, telomelysin",
author = "Lin, {Wei Hsiang} and Yeh, {Shiou Hwei} and Yang, {Wan Jen} and Yeh, {Kun Huei} and Toshiyoshi Fujiwara and Aisuke Nii and Chang, {Stanley Shi Chung} and Chen, {Pei Jer}",
year = "2013",
month = "3",
day = "15",
doi = "10.1002/ijc.27770",
language = "English",
volume = "132",
pages = "1451--1462",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice

AU - Lin, Wei Hsiang

AU - Yeh, Shiou Hwei

AU - Yang, Wan Jen

AU - Yeh, Kun Huei

AU - Fujiwara, Toshiyoshi

AU - Nii, Aisuke

AU - Chang, Stanley Shi Chung

AU - Chen, Pei Jer

PY - 2013/3/15

Y1 - 2013/3/15

N2 - The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells with high telomerase activity but not in normal cells lacking such activity. Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC. The oncolytic effect of Telomelysin has been investigated both in vitro using cell culture and in vivo using an immunocompetent in situ orthotopic HCC model. In this model, HCC developed spontaneously in the liver of HBx transgenic mice, which is pathologically and genetically similar to human HCC. In cell culture assay, Telomelysin lyses HCC cell lines at a low multiplicity of infection (MOI), ranging 0.77-6.35 (MOI [PFU/cell]). In the orthotopic HCC model, Telomelysin showed a potent oncolytic effect on HCC but spared normal liver tissue. Dose escalation analysis identified a safety dose of 1.25 × 108 PFU for this model. The effect of multiple injections of Telomelysin was also evaluated in this immunocompetent HCC model. We found that the virus replicates in HCC after a second intratumoral injection despite an immune response induced by the previous injection. This preclinical study shows that Telomelysin can be used for treatment of human HCC at an appropriate dosage and that its tumor-killing activity persists after multiple injections. What's new? More than 95 percent of hepatocellular carcinomas (HCCs) are associated with telomerase reverse transcriptase (hTERT) activation, which promotes cell immortality. In this study, the adenovirus Telomelysin demonstrated specific oncolytic activity in HCC cells with elevated hTERT. In addition, in mice with orthotopically growing HCC xenografts, the adenovirus slowed tumor growth, despite the generation of an immune response. The results suggest that Telomelysin may be useful in the treatment of HCC.

AB - The telomerase-specific replication-competent oncolytic adenovirus, Telomelysin, was developed for virus-mediated preferential lysis of tumor cells. Its selectivity is derived from a human telomerase reverse transcriptase (hTERT) promoter-driven active viral replication, which occurs in cancer cells with high telomerase activity but not in normal cells lacking such activity. Because the TERT activity is elevated in most cases of hepatocellular carcinoma (HCC), the current study aims to investigate whether Telomelysin can be used for treatment of HCC. The oncolytic effect of Telomelysin has been investigated both in vitro using cell culture and in vivo using an immunocompetent in situ orthotopic HCC model. In this model, HCC developed spontaneously in the liver of HBx transgenic mice, which is pathologically and genetically similar to human HCC. In cell culture assay, Telomelysin lyses HCC cell lines at a low multiplicity of infection (MOI), ranging 0.77-6.35 (MOI [PFU/cell]). In the orthotopic HCC model, Telomelysin showed a potent oncolytic effect on HCC but spared normal liver tissue. Dose escalation analysis identified a safety dose of 1.25 × 108 PFU for this model. The effect of multiple injections of Telomelysin was also evaluated in this immunocompetent HCC model. We found that the virus replicates in HCC after a second intratumoral injection despite an immune response induced by the previous injection. This preclinical study shows that Telomelysin can be used for treatment of human HCC at an appropriate dosage and that its tumor-killing activity persists after multiple injections. What's new? More than 95 percent of hepatocellular carcinomas (HCCs) are associated with telomerase reverse transcriptase (hTERT) activation, which promotes cell immortality. In this study, the adenovirus Telomelysin demonstrated specific oncolytic activity in HCC cells with elevated hTERT. In addition, in mice with orthotopically growing HCC xenografts, the adenovirus slowed tumor growth, despite the generation of an immune response. The results suggest that Telomelysin may be useful in the treatment of HCC.

KW - hepatocellular carcinoma

KW - immunocompetent

KW - oncolytic adenovirus

KW - orthotopic

KW - telomelysin

UR - http://www.scopus.com/inward/record.url?scp=84984580947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984580947&partnerID=8YFLogxK

U2 - 10.1002/ijc.27770

DO - 10.1002/ijc.27770

M3 - Article

VL - 132

SP - 1451

EP - 1462

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -